rMenB+OMV

BIOLOGICAL3 trials

Sponsors

Novartis Vaccines, Novartis

Conditions

HealthyMeningococcal Disease

Phase 2

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

CompletedNCT00381615

Novartis VaccinesHealthy

Start: 2006-09-30End: 2008-08-31Updated: 2015-10-09

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

CompletedNCT00433914

Novartis VaccinesMeningococcal Disease

Start: 2007-02-28End: 2008-07-31Updated: 2015-03-06

Phase 3

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

CompletedNCT02141516

NovartisMeningococcal Disease

Start: 2014-05-31End: 2015-03-31Updated: 2017-02-15

Related Papers

Synergistic activity of antibodies in the multicomponent 4CMenB vaccine.

2022-03-1421 citations